1. Home
  2. BCG vs PLUR Comparison

BCG vs PLUR Comparison

Compare BCG & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BCG

Binah Capital Group Inc.

N/A

Current Price

$1.36

Market Cap

25.4M

Sector

N/A

ML Signal

N/A

Logo Pluri Inc.

PLUR

Pluri Inc.

N/A

Current Price

$1.78

Market Cap

25.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BCG
PLUR
Founded
2016
2001
Country
United States
Israel
Employees
150
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.4M
25.5M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
BCG
PLUR
Price
$1.36
$1.78
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
15.8K
43.7K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.78
EPS
N/A
N/A
Revenue
N/A
$1,336,000.00
Revenue This Year
N/A
$97.38
Revenue Next Year
N/A
$293.97
P/E Ratio
$56.15
N/A
Revenue Growth
N/A
309.82
52 Week Low
$1.36
$1.56
52 Week High
$3.44
$5.68

Technical Indicators

Market Signals
Indicator
BCG
PLUR
Relative Strength Index (RSI) 31.51 38.86
Support Level $1.36 $1.56
Resistance Level $1.61 $2.50
Average True Range (ATR) 0.07 0.18
MACD -0.01 0.02
Stochastic Oscillator 0.00 31.61

Price Performance

Historical Comparison
BCG
PLUR

About BCG Binah Capital Group Inc.

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

About PLUR Pluri Inc.

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Share on Social Networks: